ROYALTY PHARMA PLCROYALTY PHARMA PLCROYALTY PHARMA PLC

ROYALTY PHARMA PLC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪304.20 B‬MXN
50.41MXN
‪19.28 B‬MXN
‪39.99 B‬MXN
‪381.09 M‬
Beta (1Y)
0.03
Employees (FY)
89
Change (1Y)
+14 +18.67%
Revenue / Employee (1Y)
‪449.35 M‬MXN
Net income / Employee (1Y)
‪216.58 M‬MXN

About Royalty Pharma plc


CEO
Pablo Gerardo Legorreta
Headquarters
New York
Founded
2020
ISIN
GB00BMVP7Y09
FIGI
BBG00XD2VW03
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
RPHC5222528
Royalty Pharma Plc 3.35% 02-SEP-2051
Yield to maturity
6.90%
Maturity date
Sep 2, 2051
RPHC5237919
Royalty Pharma Plc 3.55% 02-SEP-2050
Yield to maturity
6.54%
Maturity date
Sep 2, 2050
RPHC5237891
Royalty Pharma Plc 3.3% 02-SEP-2040
Yield to maturity
6.46%
Maturity date
Sep 2, 2040
RPHC5824522
Royalty Pharma Plc 5.9% 02-SEP-2054
Yield to maturity
5.88%
Maturity date
Sep 2, 2054
RPHC5222527
Royalty Pharma Plc 2.15% 02-SEP-2031
Yield to maturity
5.41%
Maturity date
Sep 2, 2031
RPHC5824521
Royalty Pharma Plc 5.4% 02-SEP-2034
Yield to maturity
5.37%
Maturity date
Sep 2, 2034
RPHC5237916
Royalty Pharma Plc 2.2% 02-SEP-2030
Yield to maturity
5.32%
Maturity date
Sep 2, 2030
RPHC5237914
Royalty Pharma Plc 1.2% 02-SEP-2025
Yield to maturity
4.93%
Maturity date
Sep 2, 2025
RPHC5237354
Royalty Pharma Plc 1.75% 02-SEP-2027
Yield to maturity
4.92%
Maturity date
Sep 2, 2027
RPHC5824520
Royalty Pharma Plc 5.15% 02-SEP-2029
Yield to maturity
4.90%
Maturity date
Sep 2, 2029
RPHC5035520
Royalty Pharma Plc 2.2% 02-SEP-2030
Yield to maturity
2.37%
Maturity date
Sep 2, 2030

Explore more bonds 

Frequently Asked Questions


The current price of RPRX/N is 528.50 MXN — it hasn't changed in the past 24 hours. Watch ROYALTY PHARMA PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange ROYALTY PHARMA PLC stocks are traded under the ticker RPRX/N.
We've gathered analysts' opinions on ROYALTY PHARMA PLC future price: according to them, RPRX/N price has a max estimate of 1,043.33 MXN and a min estimate of 572.81 MXN. Watch RPRX/N chart and read a more detailed ROYALTY PHARMA PLC stock forecast: see what analysts think of ROYALTY PHARMA PLC and suggest that you do with its stocks.
RPRX/N reached its all-time high on Jan 29, 2021 with the price of 1,052.42 MXN, and its all-time low was 448.33 MXN and was reached on May 30, 2024. View more price dynamics on RPRX/N chart.
See other stocks reaching their highest and lowest prices.
RPRX/N stock is 0.00% volatile and has beta coefficient of 0.03. Track ROYALTY PHARMA PLC stock price on the chart and check out the list of the most volatile stocks — is ROYALTY PHARMA PLC there?
Today ROYALTY PHARMA PLC has the market capitalization of ‪229.38 B‬, it has increased by 2.16% over the last week.
Yes, you can track ROYALTY PHARMA PLC financials in yearly and quarterly reports right on TradingView.
ROYALTY PHARMA PLC is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
RPRX/N earnings for the last quarter are 18.08 MXN per share, whereas the estimation was 18.28 MXN resulting in a −1.09% surprise. The estimated earnings for the next quarter are 19.87 MXN per share. See more details about ROYALTY PHARMA PLC earnings.
ROYALTY PHARMA PLC revenue for the last quarter amounts to ‪14.48 B‬ MXN, despite the estimated figure of ‪13.73 B‬ MXN. In the next quarter, revenue is expected to reach ‪12.40 B‬ MXN.
RPRX/N net income for the last quarter is ‪10.72 B‬ MXN, while the quarter before that showed ‪1.87 B‬ MXN of net income which accounts for 472.89% change. Track more ROYALTY PHARMA PLC financial stats to get the full picture.
Yes, RPRX/N dividends are paid quarterly. The last dividend per share was 4.28 MXN. As of today, Dividend Yield (TTM)% is 3.28%. Tracking ROYALTY PHARMA PLC dividends might help you take more informed decisions.
ROYALTY PHARMA PLC dividend yield was 2.85% in 2023, and payout ratio reached 31.57%. The year before the numbers were 1.92% and 777.10% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 11, 2024, the company has 89.00 employees. See our rating of the largest employees — is ROYALTY PHARMA PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROYALTY PHARMA PLC EBITDA is ‪30.42 B‬ MXN, and current EBITDA margin is 63.37%. See more stats in ROYALTY PHARMA PLC financial statements.
Like other stocks, RPRX/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROYALTY PHARMA PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROYALTY PHARMA PLC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROYALTY PHARMA PLC stock shows the sell signal. See more of ROYALTY PHARMA PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.